Delivery Order SPE2DB20D2014-SPE2DB25FB73F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,529.88 to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count units) on August 29, 2025, with completion scheduled for September 2, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,256.00 to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count supply) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,297.85 to AmerisourceBergen Drug Corp for the supply of MULTAQ 400 MG tablets (60-count units). This firm fixed price contract, with an ultimate completion date of August 4, 2025, was competitively awarded without set-aside designation. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count packages) under a firm fixed-price contract valued at $2,247.47. The award, issued on May 23, 2025, with an ultimate completion date of May 27, 2025, represents a competitive procurement with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this delivery order, which supplies pharmaceutical...
- The Defense Logistics Agency awarded a $4,824.44 delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60 count) on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed-price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract action under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count) under a firm fixed-price contract valued at $3,059.76. The order was competitively awarded without set-aside designation and is scheduled for completion by July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery from its corporate office location. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,529.88 delivery order to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count packages) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The award was competitively procured with no set-aside...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of MULTAQ 400 mg tablets (60-count packages) under a firm fixed-price contract. The award, valued at $4,604.72, represents a non-set-aside competitive award with an ultimate completion date of June 10, 2025. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $4,112.56 to AmerisourceBergen Drug Corp for the supply of MULTAQ 400 MG tablets (60-count packages) on April 28, 2025, with an ultimate completion date of April 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $1,647.26 to AmerisourceBergen Drug Corp for the supply of MULTAQ 400 mg tablets (60-unit count). This firm fixed price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. Performance will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement under the company's...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FB73FDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,529.88 to AmerisourceBergen Drug Corp for MULTAQ 400 mg tablets (60-count supply) on April 24, 2025, with an ultimate completion date of April 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and serves the federal government's pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order under its larger prime indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. This delivery order is issued under AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. As a child contract under the SPE2DX IDC, this award demonstrates the company's continued role in supporting the Defense Health Agency and other federal healthcare systems through the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 4/24/25 |